Clinical validation of a serum protein biomarker signature for the early diagnosis of pancreatic cancer.

Projektinformationen

IMMPACT

ID Finanzhilfevereinbarung: 672454

DOI 10.3030/672454

Abgeschlossenes Projekt

EK-Unterschriftsdatum 15 Juli 2015

Startdatum 1 Juni 2015

Enddatum 31 Mai 2018

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 4 244 969,25

EU-Beitrag € 4 244 969,00

Koordiniert durch

IMMUNOVIA AB
Sweden

Ziel

The IMMPACT project aims to perform the clinical validation of a serum biomarker signature for the early diagnosis of pancreatic cancer. The biomarker signature is based on the world’s most advanced recombinant antibody microarray platform owned by Immunovia AB. The underlying technology is affinity proteomics. The biomarker signature hence exploits the body’s own detection network for the diagnosis of cancer. The initial retrospective clinical studies have confirmed that the biomarker signature can accurately separate pancreatic cancer patients from healthy individuals. The implication is that the signature, once validated by a robust method, has a very high potential for the short-term uptake into clinical practice. The European dimension of the project lies in the validation of the biomarker signature that will make it possible for the first time to accurately diagnose pancreatic cancer in an asymptomatic stage (I and II) when the cancer is resectable. The results of the project will help to build up evidence that pancreatic cancer can be detected at an early stage, thus laying the basis for the future implementation of screening programmes of population groups at risk. The project stems from the unmet clinical need for the early detection of PDAC. Pancreatologists need a reliable biomarker for the early diagnosis (yes/no) diagnosis of pancreatic cancer. The test should primarily indicate whether the patient has cancer, not if the patient has a high risk of getting cancer. The new biomarker signature will address those needs and allow Immunovia to benefit from the tremendous business opportunity. Immunovia’s business strategy is based on extensive efforts towards validating the new biomarker signature by retrospective and prospective clinical trials. The validation to be undertaken in the project will accelerate an international clinical uptake of Immunovia’s blood based-tests. The project is thus fully aligned with Immunovia’s business development strategy.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › oncology › prostate cancer
• medical and health sciences › clinical medicine › surgery
• medical and health sciences › clinical medicine › oncology › breast cancer
• medical and health sciences › clinical medicine › oncology › colorectal cancer
• medical and health sciences › clinical medicine › oncology › pancreatic cancer

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• PHC-12-2014 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-2-2014

Finanzierungsplan

SME-2 - SME instrument phase 2

Koordinator

IMMUNOVIA AB

• Netto-EU-Beitrag: € 4 244 969,00
• Adresse: SCHEELEVAGEN 2 MEDICON VILLAGE ; 223 81 LUND ; Schweden
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Södra Sverige › Sydsverige › Skåne län
• Region: Södra Sverige › Sydsverige › Skåne län
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 4 244 969,25